Form 4: Nuvalent CEO James Richard Porter Reports Stock Transactions

Nuvalent's CEO, James Richard Porter, reports the acquisition and disposition of Class A Common Stock and stock options, including sales to cover tax obligations.

Summary

• On January 6, 2025, James Richard Porter, the President and CEO of Nuvalent, Inc., engaged in multiple transactions involving the company's Class A Common Stock.
• Porter acquired 56,250 shares of Class A Common Stock through restricted stock units (RSUs) at a price of $0.00 per share.
• He also sold 4,962 shares at an average price of $78.28, 2,979 shares at an average price of $79.33, and 9,360 shares at an average price of $80.54.
• These sales were executed under a pre-arranged Rule 10b5-1 plan to cover tax withholding obligations related to the vesting of previously granted equity awards.
• Additionally, Porter acquired a stock option to purchase 112,500 shares of Class A Common Stock at an exercise price of $78.09.
• The RSUs vest in three equal annual installments starting January 6, 2025, and the stock options vest in equal monthly installments over four years from the same date, both contingent upon continued service to Nuvalent, Inc.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The transactions are routine and expected, with the CEO maintaining a significant ownership stake. The use of a 10b5-1 plan adds transparency.

Positives

• The acquisition of RSUs and stock options demonstrates continued alignment of the CEO's interests with the company's long-term performance.
• The use of a pre-arranged Rule 10b5-1 plan for stock sales provides transparency and avoids potential insider trading concerns.

Industry Context

Form 4 filings are standard practice and provide transparency into the trading activities of company insiders, allowing investors to monitor potential alignment or misalignment of interests.

Comparison to Industry Standards

• Executive compensation packages often include a mix of salary, stock options, and restricted stock units (RSUs) to incentivize performance and align executive interests with shareholder value, similar to practices at companies like Amgen, Regeneron, and Vertex Pharmaceuticals.
• The use of Rule 10b5-1 trading plans is a common practice among corporate executives to manage stock sales in compliance with insider trading regulations, mirroring strategies employed by executives at companies such as Pfizer and Merck.
• The vesting schedules for RSUs and stock options, typically spanning several years, are designed to retain key personnel and encourage long-term commitment, consistent with industry standards observed at companies like Gilead Sciences and Bristol-Myers Squibb.

Stakeholder Impact

• The transactions provide transparency to shareholders regarding the CEO's stock ownership and trading activities.
• The use of a Rule 10b5-1 plan helps ensure fair and compliant trading practices.

Key Dates